Results 11 to 20 of about 2,538,615 (320)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

New England Journal of Medicine, 2022
BACKGROUND Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however ...
P. Forde, J. Spicer, Shun Lu, M. Provencio, T. Mitsudomi, M. Awad, E. Felip, S. Broderick, J. Brahmer, S. Swanson, K. Kerr, Changli Wang, T. Ciuleanu, G. Saylors, F. Tanaka, H. Ito, Keke Chen, M. Liberman, E. Vokes, J. Taube, C. Dorange, Junliang Cai, J. Fiore, A. Jarkowski, D. Balli, M. Sausen, D. Pandya, C. Calvet, N. Girard   +28 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander, M. Sill, L. Beffa, Richard G. Moore, J. Hope, Fernanda B Musa, R. Mannel, M. Shahin, G. Cantuaria, E. Girda, C. Mathews, J. Kavecansky, Charles A Leath Iii, L. Gien, E. Hinchcliff, S. Lele, L. Landrum, F. Backes, R. O'Cearbhaill, T. Al Baghdadi, E. Hill, P. Thaker, V. John, S. Welch, A. Fader, M. Powell, C. Aghajanian   +26 more
semanticscholar   +1 more source

Pneumococcal vaccination in adult patients with comorbidities: a review of the clinical practice guidelines [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2020
The review discusses national clinical practice guidelines for pneumococcal vaccination in different countries, existing approaches to adult immunization, and highlights key results of the most significant clinical studies and metaanalyses on the ...
Kozlov R.S., Andreeva I.V., Stetsiouk O.U., Muravyev A.A.   +3 more
doaj   +1 more source

Systemic analysis of the AST results in medical organizations of the Russian Feder ation [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
Objective. To analyse aggregated AST results for key microorganisms collected through the 2022 reports of chief specialists in clinical microbiology and antimicrobial resistance. Materials and Methods.
Vinogradova A.G., Kuzmenkov A.Yu., Trushin I.V., Sukhorukova M.V., Kozlov R.S.   +4 more
doaj   +1 more source

Severe anaphylaxis caused by intravenous anti‐cancer drugs

Cancer Medicine, 2021
Background The incidence and risk factors of severe anaphylaxis by intravenous anti‐cancer drugs are unclear, whereas those of milder reactions have been reported.
Nobuyuki Horita, Etsuko Miyagi, Taichi Mizushima, Maki Hagihara, Chiaki Hata, Yuki Hattori, Narihiko Hayashi, Kuniyasu Irie, Hideyuki Ishikawa, Yusuke Kawabata, Yosuke Kitani, Noritoshi Kobayashi, Nobuaki Kobayashi, Yusuke Kurita, Yohei Miyake, Kentaro Miyake, Senri Oguri, Ichiro Ota, Ayako Shimizu, Masanobu Takeuchi, Akimitsu Yamada, Kojiro Yamamoto, Norio Yukawa, Munetaka Masuda, Nobuhiko Oridate, Yasushi Ichikawa, Takeshi Kaneko   +26 more
doaj   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed ...
J. Cortés, H. Rugo, D. Cescon, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, J. Peréz-García, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Zifang Guo, Xuan Zhou, V. Karantza, W. Pan, P. Schmid   +18 more
semanticscholar   +1 more source

Antimicrobial resistance of clinical isolates of Klebsiella pneumoniae and Escherichia coli in Russian hospitals: results of a multicenter epidemiological study [PDF]

Клиническая микробиология и антимикробная химиотерапия
Objective. To study the prevalence and mechanisms of antibiotic resistance, including carbapenemase production, in clinical isolates of Klebsiella pneumoniae and Escherichia coli isolated in different regions of Russia as part of the sentinel ...
Edelstein M.V., Shajdullina E.R., Ivanchik N.V., Dekhnich A.V., Mikotina A.V., Skleenova E.Yu., Sukhorukova M.V., Azyzov I.S., Shek E.A., Romanov A.V., Trushin I.S., Kuzmenkov A.Yu., Kozlov R.S.   +12 more
doaj   +1 more source

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD‐L1) of 50% or greater ...
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino   +28 more
semanticscholar   +1 more source

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2016
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1 ...
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman B. Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma A. Rangwala, J. Brahmer   +17 more
semanticscholar   +1 more source

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Nature, 2022
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma1–4.
K. Shitara, J. Ajani, M. Moehler, M. Garrido, C. Gallardo, L. Shen, K. Yamaguchi, L. Wyrwicz, T. Skoczylas, A. Bragagnoli, Tianshu Liu, M. Tehfé, E. Elimova, R. Brugés, T. Zander, Sergio Jobim de Azevedo, R. Kowalyszyn, R. Pazo-Cid, M. Schenker, J. Cleary, P. Yanez, K. Feeney, M. Karamouzis, V. Poulart, M. Lei, H. Xiao, K. Kondo, Mingshun Li, Y. Janjigian   +28 more
semanticscholar   +1 more source